Higher Lp(a) Threshold More Closely Linked to Major ASCVD Events

Why It Matters

Recognizing ≥ 175 nmol/L as a high‑risk threshold could reshape risk‑enhancement strategies, prompting earlier LDL‑lowering and informing patient selection for emerging Lp(a)‑lowering drugs. This shift may improve outcomes for patients with residual cardiovascular risk despite optimal lipid control.

Key Takeaways

• Lp(a) ≥ 175 nmol/L predicts death, CV death, stroke over 7 years
• Risk at ≥ 175 nmol/L rivals that of current smokers
• Guideline threshold (125 nmol/L) may underestimate high‑risk patients
• Ongoing trials (olpasiran, lepodisiran, pelacarsen) target Lp(a) reduction
• Secondary‑prevention patients show strongest population‑attributable risk from high Lp(a)

Pulse Analysis

Lipoprotein(a) has long been a silent contributor to cardiovascular disease, but its clinical relevance has been hampered by an ambiguous risk threshold. The new pooled analysis of ACCORD, PEACE and SPRINT trials clarifies that a level of ≥ 175 nmol/L, not the previously cited 125 nmol/L, is a robust independent predictor of all‑cause death, cardiovascular mortality and stroke. By adjusting for traditional risk factors, the study demonstrates that patients crossing this higher cutoff face a hazard ratio approaching that of active smokers, underscoring the potency of Lp(a) as a residual risk factor.

The implications for practice are immediate. Current ACC/AHA guidelines treat Lp(a) ≥ 125 nmol/L as a risk‑enhancer, prompting intensified LDL‑cholesterol management. However, the data suggest that clinicians may be missing a subset of patients whose Lp(a) sits between 125 and 175 nmol/L yet still carries substantial risk, especially in secondary‑prevention cohorts. Physicians are likely to adopt more aggressive lipid‑lowering strategies, incorporate coronary calcium scoring, and consider early enrollment in Lp(a)‑targeted therapy trials for those exceeding the 175 nmol/L threshold.

The timing aligns with a wave of novel therapeutics aimed at directly lowering Lp(a). Phase‑III trials such as OCEAN(a) (olpasiran), ACCLAIM‑Lp(a) (lepodisiran) and Lp(a)HORIZON (pelacarsen) are evaluating siRNA and antisense approaches that could dramatically reduce Lp(a) concentrations. As these agents near regulatory approval, a clearer, evidence‑backed threshold will be essential for patient selection, reimbursement decisions, and public‑health policies aimed at curbing the residual cardiovascular burden. The emerging consensus points toward integrating routine Lp(a) testing into cath‑lab workflows and refining guideline cutoffs to reflect the newly identified risk plateau.